Alaris says AmeriNet deal worth $150 million:
This article was originally published in Clinica
Executive Summary
Alaris Medical has signed a five-year dual source agreement with AmeriNet for drug infusion devices and disposables, which, says Alaris, is worth $150 million over the life of the contract. The deal with the US group purchasing organisation (GPO), which represents 8,000 member facilities and more than 350,000 beds, also includes San Diego-based Alaris' SmartSite needle-free valves.
You may also be interested in...
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.